On Nov 13, major Wall Street analysts update their ratings for $Axsome Therapeutics (AXSM.US)$, with price targets ranging from $116 to $150.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and adjusts the target price from $115 to $125.
BofA Securities analyst Jason Gerberry maintains with a buy rating, and adjusts the target price from $106 to $118.
Wells Fargo analyst Cerena Chen maintains with a buy rating, and maintains the target price at $140.
TD Cowen analyst Joseph Thome maintains with a buy rating, and adjusts the target price from $120 to $125.
Guggenheim analyst Yatin Suneja maintains with a buy rating, and sets the target price at $135.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
Following a third-quarter update, which included surpassing revenue expectations and positive pipeline developments, an analyst has maintained a positive outlook on Axsome Therapeutics. Clarifications regarding the schedule of two concurrent Phase 3 Auvelity ADA trials have delineated the timeline of upcoming catalyst events, with expectations for simultaneous study results in the fourth quarter. It's believed that success in either one of the ADA trials could dispel any lingering concerns over the regulatory outlook for this significant label expansion.
The recent quarter was notably strong for Axsome Therapeutics, chiefly attributed to a promising increase in Auvelity sales. The company remains a top selection due to the belief that its stock possesses the most compelling series of catalysts through the end of the year in the coverage universe.
Here are the latest investment ratings and price targets for $Axsome Therapeutics (AXSM.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月13日，多家华尔街大行更新了$Axsome Therapeutics (AXSM.US)$的评级，目标价介于116美元至150美元。
摩根士丹利分析师Vikram Purohit维持买入评级，并将目标价从115美元上调至125美元。
美银证券分析师Jason Gerberry维持买入评级，并将目标价从106美元上调至118美元。
富国集团分析师Cerena Chen维持买入评级，维持目标价140美元。
TD Cowen分析师Joseph Thome维持买入评级，并将目标价从120美元上调至125美元。
Guggenheim分析师Yatin Suneja维持买入评级，目标价135美元。
此外，综合报道，$Axsome Therapeutics (AXSM.US)$近期主要分析师观点如下：
在第三季度更新后，分析师对axsome therapeutics的前景保持乐观态度，这次更新包括超过营业收入预期和积极的产品线进展。关于两项同时进行的第三阶段Auvelity ADA试验的时间表的澄清，已经明确了即将到来的催化事件的时间线，预计在第四季度同时得到研究结果。人们相信，在任一ADA试验中的成功可以消除对这一重大标签扩展的监管前景的任何担忧。
最近一个季度对axsome therapeutics来说特别强劲，主要是由于Auvelity销售的显著增长。由于相信其股票在覆盖范围内到年底拥有最具吸引力的一系列催化剂，该公司仍然是一个热门选项。
以下为今日10位分析师对$Axsome Therapeutics (AXSM.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
